Preparation and Characterization of Tacrolimus-Loaded SLNs in situ Gel for Ocular Drug Delivery for the Treatment of Immune Conjunctivitis

References

• MauriceDM. Kinetics of topical applied drugs In: SaettoneMS, BucciP, SpeiserP, editors. Ophthalmic Drug Delivery: Biopharmaceutical, Technological and Clinical Aspects. Padova: Liviana Press; 1987:19–26.
   Google Scholar
• PleyerU, LutzS, JuskoW, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in rabbit eye. Invest Ophthalmol Vis Sci. 1993;34(9):2737–2742.7688360
   PubMed Web of Science ®Google Scholar
• BochotA, FattalE, GrossiordJL, PuisieuxF, CouvereurP. Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. Int J Pharm. 1998;162:119–127. doi:10.1016/S0378-5173(97)00419-5
   Web of Science ®Google Scholar
• de CamposAM, DieboldY, CarvaihoEL, SanchezA, AlonsoMJ. Chitosan nanoparticles as new ocular drug delivery system: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res. 2004;21(5):803–810. doi:10.1023/B:PHAM.0000026432.75781.cb15180338
   PubMed Web of Science ®Google Scholar
• NayakK, MisraM, NayakK, et al. A review on recent drug delivery systems for posterior segment of eye. Biomed Pharmacother. 2018;107:1564–1582. doi:10.1016/j.biopha.2018.08.13830257375
   PubMed Web of Science ®Google Scholar
• BachuRD, ChowdhuryP, Al-SaediZHF, et al. Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018;10(1):28. doi:10.3390/pharmaceutics10010028
   PubMed Web of Science ®Google Scholar
• De CamposAM, SánchezA, GrefR, CalvoP, AlonsoMJ. The effect of PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci. 2003;20(1):73–81. doi:10.1016/S0928-0987(03)00178-713678795
   PubMed Web of Science ®Google Scholar
• LakhaniP, PatilA, MajumdarS, et al. Recent advances in topical nano drug-delivery systems for the anterior ocular segment. Ther Deliv. 2018;9(2):137–153. doi:10.4155/tde-2017-008829325511
   PubMed Web of Science ®Google Scholar
• FerraboschiP, ColomboD, De MieriM, et al. Evaluation, synthesis and characterization of tacrolimus impurities. J Antibiot (Tokyo). 2012;65(7):349–354. doi:10.1038/ja.2012.2822511227
   PubMed Web of Science ®Google Scholar
• HonboT, KobayashiM, HaneK, HataT, UedaY. The oral dosage form of FK-506. Transplant Proc. 1987;19(5 Suppl 6):17–22.
   PubMed Web of Science ®Google Scholar
• ArimaH, YunomaeK, MiyakeK, IrieT, HirayamaF, UekamaK. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci. 2001;90(6):690–701. doi:10.1002/jps.102511357172
   PubMed Web of Science ®Google Scholar
• GaoS, SunJ, FuD, ZhaoH, LanM, GaoF. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. Int J Pharm. 2012;427(2):410–416. doi:10.1016/j.ijpharm.2012.01.05422326299
   PubMed Web of Science ®Google Scholar
• KwonM, YeomD, KimNA, et al. Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. Arch Pharm Res. 2015;38(1):73–80. doi:10.1007/s12272-014-0343-324627339
   PubMed Web of Science ®Google Scholar
• SkytteDM, JaroszewskiJW, JohansenKT, et al. Some transformations of tacrolimus, an immunosuppressive drug Eur. J Pharm Sci. 2013;48(3):514–522.
   Web of Science ®Google Scholar
• LoftssonT, MuellertzA, SiepmannJ. For the special IJP issue “Poorly soluble drugs”. Int J Pharm. 2013;453(1):1–2. doi:10.1016/j.ijpharm.2013.05.05623742971
   PubMed Web of Science ®Google Scholar
• XiaoP, DudalY, CorviniP, SpahrP, ShahgaldianP. Synthesis and characterization of fluoroquinolone-imprinted polymeric nanoparticles. React Funct Polym. 2012;72:287–293. doi:10.1016/j.reactfunctpolym.2012.02.006
   Web of Science ®Google Scholar
• MüllerRH, MäderK, GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177. doi:10.1016/S0939-6411(00)00087-410840199
   PubMed Web of Science ®Google Scholar
• MehnertW, MäderK. Solid lipid nanoparticles. production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–196. doi:10.1016/S0169-409X(01)00105-311311991
   PubMed Web of Science ®Google Scholar
• KhamesA, KhaleelMA, El-BadawyMF, El-NezhawyAOH. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization. Int J Nanomedicine. 2019;14:2515–2531. doi:10.2147/IJN.S19050231040672
   PubMed Web of Science ®Google Scholar
• TatkeA, DudhipalaN, JangaKY, et al. In situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: tear kinetics and ocular disposition studies. Nanomaterials (Basel). 2018;9(1):33. doi:10.3390/nano9010033
   Google Scholar
• BalguriSP, AdelliGR, MajumdarS. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm. 2016;109:224–235. doi:10.1016/j.ejpb.2016.10.01527793755
   PubMed Web of Science ®Google Scholar
• YadavM, SchiavoneN, Guzman-AranguezA, et al. Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD). Drug Deliv Transl Res. 2020;10(4):919–944. doi:10.1007/s13346-020-00733-432270439
   PubMed Web of Science ®Google Scholar
• NarendarD, KishanV. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23(2):395–404. doi:10.3109/10717544.2014.91498624865287
   PubMed Web of Science ®Google Scholar
• YuL, ZhangZ, ZhangH, DingJ. Biodegradability and biocompatibility of thermoreversible hydrogels formed from mixing a sol and a precipitate of block copolymers in water. Biomacromolecules. 2010;11(8):2169–2178. doi:10.1021/bm100549q20690723
   PubMed Web of Science ®Google Scholar
• RakeshK, SinhaVR. Solid lipid nanoparticle: an efficient carrier for improved ocular permeation of voriconazole. Drug Dev Ind Pharm. 2016;42(12):1956–1967. doi:10.1080/03639045.2016.118543727143048
   PubMed Web of Science ®Google Scholar
• GiannavolaC, BucoloC, MalteseA, et al. Influence of preparation conditions on acyclovir- loaded poly-d, l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res. 2003;20(4):584–590. doi:10.1023/A:102329051457512739765
   PubMed Web of Science ®Google Scholar
• SrividyaB, CardozaRM, AminPD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in-situ gelling system. J Control Release. 2001;73(2–3):205–211. doi:10.1016/S0168-3659(01)00279-611516498
   PubMed Web of Science ®Google Scholar
• MoreiraTS, de SousaVP, PierreMB. Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels. J Pharm Pharm Sci. 2010;13(2):286–302. doi:10.18433/J3488020816013
   PubMed Web of Science ®Google Scholar
• PerezAP, Mundiña-WeilenmannC, RomeroEL, MorillaMJ. Increased brain radioactivity by intranasal P-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels. Int J Nanomedicine. 2012;7:1373–1385. doi:10.2147/IJN.S2826122457595
   PubMed Web of Science ®Google Scholar